Kyntra Bio, Inc.
KYNB
NASDAQ·Healthcare·Biotechnology·Mkt cap $34.6M
$8.55
▲ +0.71%
P/E
—
Mkt Cap
$34.6M
52-Wk Range
$6.32–$12.58
52-Week Range
$6.32 - $12.58
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 23.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary HIF and CTGF biology platform technology
- Experienced management team with deep biopharmaceutical expertise
- First-mover advantage in novel mechanism space
- Strategic focus on high-prevalence, high-value therapeutic areas
Bear Case
1 risk
- Average volatility.
Growth
Profitability at risk
Clinical trial advancement and regulatory approvals
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+27.4% over 3m
Quality
Thin
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying KYNB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 13, 2026
Reported EPS of $2.96 vs -$3.18 consensus (+193.1% surprise). Revenue of $-1.5M vs $2.1M expected (-171.8%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+193.1%
Revenue trend · last 8Q
—
—
-89%
+35%
-98%
+101%
+36%
-209%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$46.3M
-$123.3M
$2.7M
$1.3M
$1.1M
$1.3M
$3.7M
-$1.5M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
—
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Jul 6, 2026
vs Industry
How KYNB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.